These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31918728)

  • 1. Repeated CyberKnife stereotactic body radiation therapy in hepatocellular carcinoma.
    Sun J; Ouyang C; Chang X; Zhang A; Wang Q; Li W; Zhang D; Wang J; Li D; Duan X
    Radiat Oncol; 2020 Jan; 15(1):10. PubMed ID: 31918728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
    Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
    BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologically effective dose (BED) escalation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma patients (≤5 cm) with CyberKnife: protocol of study.
    Sun J; Zhang A; Li W; Wang Q; Li D; Zhang D; Duan X
    Radiat Oncol; 2020 Jan; 15(1):20. PubMed ID: 31992327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.
    Kimura T; Takeda A; Tsurugai Y; Kawano R; Doi Y; Oku Y; Hioki K; Miura H; Nagata Y
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1265-1275. PubMed ID: 32712256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
    Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
    BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis.
    Sun J; Wang Q; Hong ZX; Li WG; He WP; Zhang T; Zhang AM; Fan YZ; Sun YZ; Zheng L; Duan XZ
    Hepatol Int; 2020 Sep; 14(5):788-797. PubMed ID: 32886334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
    Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
    Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
    Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
    Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma.
    Park S; Jung J; Cho B; Kim SY; Yun SC; Lim YS; Lee HC; Park J; Park JH; Kim JH; Yoon SM
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1953-1959. PubMed ID: 32052884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
    Rim CH; Kim HJ; Seong J
    Radiother Oncol; 2019 Feb; 131():135-144. PubMed ID: 30773180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series.
    Wang YF; Dai YH; Lin CS; Chang HC; Shen PC; Yang JF; Hsiang CW; Lo CH; Huang WY
    Radiat Oncol; 2021 Jan; 16(1):15. PubMed ID: 33446231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma.
    Moore A; Cohen-Naftaly M; Tobar A; Kundel Y; Benjaminov O; Braun M; Issachar A; Mor E; Sarfaty M; Bragilovski D; Hur RB; Gordon N; Stemmer SM; Allen AM
    Radiat Oncol; 2017 Oct; 12(1):163. PubMed ID: 29052532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.
    Kim JW; Seong J; Lee IJ; Woo JY; Han KH
    Oncotarget; 2016 Jun; 7(26):40756-40766. PubMed ID: 27213593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
    Andolino DL; Johnson CS; Maluccio M; Kwo P; Tector AJ; Zook J; Johnstone PA; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e447-53. PubMed ID: 21645977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting.
    Gerum S; Heinz C; Belka C; Walter F; Paprottka PM; De Toni EN; Roeder F
    Strahlenther Onkol; 2020 Apr; 196(4):334-348. PubMed ID: 31732784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma.
    Kim JW; Kim DY; Han KH; Seong J
    Dig Liver Dis; 2019 Mar; 51(3):445-451. PubMed ID: 30503296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.